TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8313315
Drug: FUDR (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUDR (0.3 mg/kg/day) with leucovorin (15 mg/m2/day) for 2 weeks followed by a 2‐week rest (Group F)
Study: 8313315
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial chemotherapy with FUDR and leucovorin
Study: 8313315
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of leucovorin (15 mg/m2) with FUDR
Study: 3042310
Drug: BAYm 1099
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAYm 1099 (50 mg 3 times/day)
Study: 28544774
Drug: Hetrombopag (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag (5 mg, 10 mg, 20 mg, 30 mg, 40 mg single dose)
Study: 28544774
Drug: Hetrombopag (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag (2.5 mg, 5.0 mg, 7.5 mg once daily for 10 days)
Study: 22004303
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (E‐TAU)
Study: 15975966
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg subcutaneous injection, twice weekly for three months)
Study: 12883465
Drug: Liposomal ACY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal ACY gel (LAG) applied five times daily for up to eight weeks
Study: 12883465
Drug: Plain ACY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain ACY gel (PAG)
Study: 10856268
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg omapatrilat
Study: 2428668
Drug: Synchronous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronous chemotherapy
Study: 31280100
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (IV-morphine)
Study: 24088075
Drug: V7 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: V7 (10 µg heat-killed Mycobacterium vaccae)
Study: 14514588
Drug: Usual glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual glucose-lowering therapy
Study: 8969731
Drug: Pause in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pause in rhGH therapy (group 1) for a mean duration of 25.5 +/- 26.9 months.
Study: 8969731
Drug: Resumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resumption of rhGH therapy after a pause (group 2) for a mean duration of 9.0 +/- 4.6 months.
Study: 8969731
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of rhGH therapy at the time of transplantation (30 patients).
Study: 8969731
Drug: Post-transplantation growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplantation growth velocity after discontinuation of rhGH therapy.
Study: 8969731
Drug: Delta height
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta height SDS at last follow-up after discontinuation of rhGH therapy.
Study: 1471603
Drug: Beta-receptor antagonists
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-receptor antagonists
Study: 7836511
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (200 mg)
Study: 6327758
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (400 mg) at 1400 h
Study: 6327758
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (400 mg) with dexamethasone (1 mg) at 2400 h
Study: 21981375
Drug: CS20 protective
Normalized name: DENTAL PROTECTANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS20 protective barrier gel
Study: 19030969
Drug: Early Gp
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Gp IIb‐IIIa inhibitors
Study: 31376908
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (placebo or acetylsalicylic acid 100 mg daily)
Study: 27121793
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus irinotecan (CAPIRI) therapy
Study: 18341819
Drug: Positive autoantibodies
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive autoantibodies against AT(1)-receptor
Study: 18341819
Drug: Negative autoantibodies
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative autoantibodies against AT(1)-receptor
Study: 20568977
Drug: iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol 320 mgI/ml
Study: 11870488
Drug: iotrolan 300
Normalized name: Iotrolan
DrugBank: Iotrolan (DB09487)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iotrolan 300 mgI/ml
Study: 31446510
Drug: Clinical pathway
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pathway treatment (n=17)
Study: 27367794
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (BCAA), arginine, and citrulline (0.17 g/kg BCAA, 0.05 g/kg arginine, 0.05 g/kg citrulline)
Study: 26516908
Drug: Oligofructose-enriched inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oligofructose-enriched inulin (5 g)
Study: 23238663
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (1.8 g eicosapentaenoic acid and 1.5 g docosahexaenoic acid)
Study: 23238663
Drug: Identical olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical olive oil capsules (placebo)
Study: 17625310
Drug: Continuous regional
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regional arterial infusion of a protease inhibitor
Study: 1657506
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of aspirin daily in the morning
Study: 1657506
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of aspirin four times a day
Study: 1657506
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg four times a day)
Study: 1657506
Drug: Enteric coating
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coating of aspirin
Study: 27418597
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d without loading dose) plus Aspirin (300 mg loading followed by 100 mg/d)
Study: 27418597
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg loading followed by 100 mg/d)
Study: 23107508
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of nicotine
Study: 19767012
Drug: Pro-constancy condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro-constancy condition (fixed biological traits)
Study: 19767012
Drug: Anti-constancy condition
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-constancy condition (mutable biological traits)
Study: 18386234
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg/kg IV (Group I)
Study: 18386234
Drug: Meperidine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.3 mg/kg IV followed by midazolam 0.05 mg/kg IV (Group II)
Study: 10436098
Drug: Aspirin (antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (antiplatelet medication)
Study: 10436098
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin (control group)
Study: 7775993
Drug: Mailed feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mailed feedback on prescribing profiles and treatment recommendations for insomnia and acute cystitis
Study: 479383
Drug: Penbutolol 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 25 to 75 mg twice daily (group A)
Study: 479383
Drug: Penbutolol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 50 to 150 mg twice daily (group B)
Study: 31054396
Drug: Tree thinning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tree thinning treatments
Study: 7601015
Drug: Fleroxacin 200
Normalized name: fleroxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 200 mg or 400 mg once daily for uncomplicated urinary tract infections
Study: 7601015
Drug: Fleroxacin 200
Normalized name: fleroxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 200 mg or 400 mg single oral dose for gonorrhoea
Study: 7601015
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for complicated urinary tract infections
Study: 7601015
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for lower respiratory tract infections
Study: 7601015
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for skin and soft tissue infections
Study: 7601015
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for pyelonephritis
Study: 7601015
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for bacterial enteritis
Study: 7601015
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for typhoid fever
Study: 7601015
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily for bone and joint infections (preliminary studies)
Study: 7601015
Drug: Fleroxacin 200
Normalized name: fleroxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 200 mg/day orally or 400 mg/day orally or intravenously
Study: 7601015
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily compared to ofloxacin 800 mg/day
Study: 7601015
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily compared to ciprofloxacin 1000 mg/day
Study: 7601015
Drug: Fleroxacin 200
Normalized name: fleroxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 200 mg once daily compared to norfloxacin 800 mg/day
Study: 2253290
Drug: Mepivacaine 1.5%
Normalized name: mepivacaine 1.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 1.5% (0.35 ml.kg‐1) + norepinephrine (5 micrograms.ml‐1)
Study: 27595693
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine U100 (IGlar)
Study: 22948779
Drug: Activated carbon
Normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated carbon nanoparticle-epirubicin suspension
Study: 20859315
Drug: Topical ibuprofen
Normalized name: ibuprofen Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ibuprofen (4% gel, 320 mg total, 4 times daily for 2 weeks)
Study: 20859315
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (2400 mg total, 3 times daily for 2 weeks)
Study: 18420964
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (22 g/d loading for 5 days; maintenance 3.76 g/d during PR)
Study: 12651678
Drug: Lidocaine 1.5%
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5% with epinephrine 1:200,000 (3 mL)
Study: 12651678
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline (3 mL)
Study: 11200792
Drug: Oral lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lysine acetylsalicylate (1620 mg) combined with metoclopramide (10 mg)
Study: 8804681
Drug: Nicotine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (20 micrograms/kg per dosing)
Study: 8804681
Drug: Nicotine combined
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine combined with alcohol (0.5 g/kg)
Study: 8804681
Drug: Alcohol alone
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol alone (0.5 g/kg)
Study: 1545087
Drug: Standardized allergen
Normalized name: cat hair standardized allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized allergen extracts (100,000, 10,000, and 1000 AU/ml)
Study: 6432415
Drug: Auranofin 3
Normalized name: auranofin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin 3 mg b.d.
Study: 6432415
Drug: Hydroxychloroquine 200
Normalized name: hydroxychloroquine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 200 mg b.d.
Study: 30871608
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin threshold of 9 g/dL)
Study: 30871608
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (hemoglobin threshold of 7 g/dL)
Study: 20558806
Drug: 10-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-week group intervention plus transdermal nicotine replacement
Study: 16244488
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of 3 million IU of recombinant interleukin‐2 (rIL‐2) left intracyst after transvaginal ultrasound-guided drainage
Study: 16244488
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 3 million IU of recombinant interleukin‐2 (rIL‐2) left intracyst after transvaginal ultrasound-guided drainage
Study: 10211174
Drug: Bupropion sustained-release
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion sustained-release at 100, 150, or 300 mg/day for six weeks after target quit date (TQD)
Study: 10211174
Drug: Bupropion sustained-release
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion sustained-release
Study: 24423476
Drug: Dexamethasone infusion
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone infusion
Study: 176034
Drug: Ethacrynic acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic acid administration
Study: 176034
Drug: Ethacrynic acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic acid administration with both renin and ACTH suppression
Study: 23714270
Drug: Economic support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Economic support (monthly voucher of ZAR120.00)
Study: 10859436
Drug: Alpha-adrenergic receptor
Normalized name: Alpha-adrenergic receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-adrenergic receptor antagonists (alpha-blockers) including prazosin, alfuzosin, indoramin, terazosin, doxazosin, and tamsulosin.
Study: 10859436
Drug: Tamsulosin (alpha(1a)-receptor-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (alpha(1a)-receptor-selective blocker).
Study: 10859436
Drug: Other less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other less selective alpha-blockers.
Study: 1557677
Drug: Ten weekly
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten weekly sessions of counselling for parents of patients
Study: 1557677
Drug: Standard after-care
Normalized name: DIMETHICONE 4 mg in 1 mL TOPICAL CREAM [AFTER CARE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard after-care of medication and support
Study: 28540870
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg OD
Study: 26189154
Drug: Combination intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intervention strategy (CIS) including point‐of‐care CD4 testing, accelerated ART initiation, mobile phone appointment reminders, care and prevention packages, non‐cash financial incentives for linkage and retention.
Study: 23321216
Drug: Self-administered OGTT
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered OGTT at home (unaided)
Study: 23321216
Drug: Self-administered OGTT
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered OGTT in clinic (unaided but observed)
Study: 23321216
Drug: Self-administered OGTT
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered OGTT performed by a nurse with laboratory glucose assays
Study: 22009649
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (Group A)
Study: 9543129
Drug: Oral etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral etidronate 400 mg/day for 14 days, followed by 76 days of oral calcium carbonate (500 mg elemental calcium), cycled over 12 months.
Study: 9543129
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14 days, followed by 76 days of oral calcium carbonate (500 mg elemental calcium), cycled over 12 months.
Study: 2724504
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine sulfate (6 mg)
Study: 31058640
Drug: Test solutions
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test solutions
Study: 24195206
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with Wenxin granule (9 g, 3 times a day for 4 weeks)
Study: 24195206
Drug: Wenxin granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wenxin granule alone (9 g, 3 times a day for 4 weeks)
Study: 22145388
Drug: Ingavirin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingavirin (90 mg once a day)
Study: 22145388
Drug: Oseltamivir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (150 mg twice a day)
Study: 16357613
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) with methotrexate (20 mg/week)
Study: 15612659
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules containing Bifidobacterium, Lactobacillus acidophilus and Enterococcus for 14 days
Study: 15612659
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules containing Bacillus subtilis and Enterococcus faecium for 14 days
Study: 3789471
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (salbutamol)
Study: 27459523
Drug: AZD4901 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4901 80 mg/day
Study: 24899360
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (200 mg capsules containing 65 mg of iron), taken at mealtimes twice daily for one week.
Study: 24899360
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken at mealtimes twice daily for one week.
Study: 24899360
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (200 mg capsules containing 65 mg of iron), during the wash-out week.
Study: 19029275
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (50 mg/kg for 4 days)
Study: 19029275
Drug: Monthly intravenous
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intravenous cyclophosphamide (750 mg/m²)
Study: 12412870
Drug: Formula supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula supplemented with docosahexaenoic acid (0.015 g/100 ml) and arachidonic acid (0.031 g/100 ml)
Study: 6218927
Drug: Mefloquine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 20 mg/kg in children
Study: 6218927
Drug: Mefloquine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 30 mg/kg in children
Study: 6218927
Drug: Mefloquine 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 750 mg in adults
Study: 6218927
Drug: Mefloquine 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 1000 mg in adults
Study: 6218927
Drug: Mefloquine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (any dose)
Study: 23731922
Drug: Intracoronary nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicorandil (4 mg)
Study: 10550135
Drug: Paclitaxel (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (250 mg/m²) as 24-hour infusion
Study: 10550135
Drug: FAC (fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC (fluorouracil, doxorubicin, and cyclophosphamide in standard doses at every-3-week intervals)
Study: 7845867
Drug: Chemo-endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-endocrine therapy (orchiectomy and/or diethylstilbestrol diphosphate (DES-DP) plus Cisplatin, with or without other cytotoxic agents)
Study: 2104073
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate 120 mg q.d.s.
Study: 2104073
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate 240 mg b.d.
Study: 7043713
Drug: Dextropropoxyphene hydrochloride-paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene hydrochloride-paracetamol (Cosalgesic)